While most mRNA-based tumor vaccine studies in the literature focus exclusively on the administration of mRNA encoding tumor antigens [37,38], this study additionally used siRNA targeting CTLA-4, one of the major immunosuppressive mechanisms. The gene discussed is CTLA4; the disease is neoplasm.